Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

CStone Pharmaceuticals (HK:2616)

HKEX:2616

2616

CStone Pharmaceuticals

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding HK:2616?

Track your performance easily

Link Broker

CStone Pharmaceuticals (2616) Stock Price & Analysis

0 Followers

2616 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$0.80 - HK$2.95

Previous CloseHK$1.53

Volume2.31M

Average Volume (3M)1.00M

Market Cap

HK$1.93B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Mar 20, 2025

EPS Estimate

-HK$0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares OutstandingN/A

10 Day Avg. Volume1,029,945

30 Day Avg. Volume1,003,940

Standard Deviation0.16

R-Squared0.09

Alpha-0.02

Financial Highlights & Ratios

Price to Book (P/B)0.00

Price to Sales (P/S)8.23

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

CStone Pharmaceuticals News

PremiumCompany Announcements

CStone Announces Promising NSCLC Treatment Data

4d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Achieves Profitable Turnaround

28d ago

2616

PremiumCompany Announcements

CStone’s AYVAKIT Wins China NMPA Approval

1M ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Schedules Key Board Meeting

1M ago

2616

PremiumCompany Announcements

CStone’s Cancer Drug Wins European Approval

2M ago

2616

PremiumCompany Announcements

CStone Pharma Advances Cancer Treatment with Strategic Deal

3M ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Announces Secretarial Changes

3M ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Shareholders Approve Resolutions

3M ago

2616

See More HK:2616 News >

Options Prices

Currently, No data available

---

Ownership Overview

0.00%

Insiders

1.13% Mutual Funds

0.61% Other Institutional Investors

98.26% Public Companies and

Individual Investors

Detailed Ownership Overview >

2616 FAQ

What was CStone Pharmaceuticals’s price range in the past 12 months?

CStone Pharmaceuticals lowest stock price was HK$0.80 and its highest was HK$2.95 in the past 12 months.

What is CStone Pharmaceuticals’s market cap?

Currently, no data Available

When is CStone Pharmaceuticals’s upcoming earnings report date?

CStone Pharmaceuticals’s upcoming earnings report date is Mar 20, 2025 which is in 181 days.

How were CStone Pharmaceuticals’s earnings last quarter?

CStone Pharmaceuticals released its earnings results on Aug 23, 2024. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of -HK$0.11 by HK$0.121.

Is CStone Pharmaceuticals overvalued?

According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CStone Pharmaceuticals pay dividends?

CStone Pharmaceuticals does not currently pay dividends.

What is CStone Pharmaceuticals’s EPS estimate?

CStone Pharmaceuticals’s EPS estimate is -HK$0.03.

How many shares outstanding does CStone Pharmaceuticals have?

CStone Pharmaceuticals has 1,284,207,200 shares outstanding.

What happened to CStone Pharmaceuticals’s price movement after its last earnings report?

CStone Pharmaceuticals reported an EPS of HK$0.011 in its last earnings report, beating expectations of -HK$0.11. Following the earnings report the stock price went down -2.29%.

Which hedge fund is a major shareholder of CStone Pharmaceuticals?

Currently, no hedge funds are holding shares in HK:2616

---

CStone Pharmaceuticals Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-26.64%

Trailing 12-Months

Asset Growth

-8.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CStone Pharmaceuticals

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

---

2616 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"HK$4","-1":"-HK$1","0.25":"HK$0.25","1.5":"HK$1.5","2.75":"HK$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,1.366153846153846,1.2523076923076923,1.1384615384615384,1.0246153846153847,0.9107692307692308,0.7969230769230768,0.683076923076923,0.5692307692307692,0.4553846153846153,0.34153846153846157,0.22769230769230764,0.11384615384615371,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,1.366153846153846,1.2523076923076923,1.1384615384615384,1.0246153846153847,0.9107692307692308,0.7969230769230768,0.683076923076923,0.5692307692307692,0.4553846153846153,0.34153846153846157,0.22769230769230764,0.11384615384615371,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,1.366153846153846,1.2523076923076923,1.1384615384615384,1.0246153846153847,0.9107692307692308,0.7969230769230768,0.683076923076923,0.5692307692307692,0.4553846153846153,0.34153846153846157,0.22769230769230764,0.11384615384615371,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.55,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.21,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.49,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.23,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.12,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.27,"date":1703808000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >